ESMO Congress 2023
![ESMO23_20.10_GUProstate_Proffered_Audience](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_guprostate_proffered_audience/18320784-1-eng-GB/esmo23_20.10_guprostate_proffered_audience_i770.jpg)
Phase III data confirm that adjuvant radiotherapy has no benefit following radical prostatectomy
Final results from the RADICALS-RT trial show that observation with salvage RT for prostate-specific antigen failure should be the current standard strategy after surgery
![ESMO23_20.10_NSCLC Proffered_Borghaei](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_nsclc-proffered_borghaei/18320778-1-eng-GB/esmo23_20.10_nsclc-proffered_borghaei_i770.jpg)
Sitravatinib plus nivolumab does not improve survival in NSCLC after immunotherapy and chemotherapy
The SAPPHIRE trial failed to meet its primary endpoint compared with chemotherapy
![MainImage_Placeholder_Interview_Ray-Coquard](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/coverage_placeholders/mainimage_placeholder_interview_ray-coquard/18270897-1-eng-GB/mainimage_placeholder_interview_ray-coquard_i770.jpg)
Checkpoint inhibition improves outcomes in high-risk, locally advanced cervical cancer
In the KEYNOTE-A18 study, the combination of pembrolizumab and concurrent chemoradiotherapy significantly improved progression-free survival
![ESMO23_20.10_NSCLC Proffered_Q&A](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_nsclc-proffered_q-a/18320724-1-eng-GB/esmo23_20.10_nsclc-proffered_q-a_i770.jpg)
Longer PFS reported with a quadruple treatment regimen in EGFR- or ALK-mutated NSCLC
Promising data from the ATTLAS phase III study indicate a potential new approach for treating patients progressing on TKIs
![Delegates_Entrance](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/delegates_entrance/18319323-1-eng-GB/delegates_entrance_i770.jpg)
Study data show a significant benefit of neoadjuvant immunotherapy in HR-positive early breast cancer for the first time
Efficacy of PD-1 inhibitors in this setting reflects that reported in triple-negative breast cancer and is confirmed by long-term data presented at the ESMO Congress
![ESMO23_20.10_GI Proferred_Lordick](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_gi-proferred_lordick/18320490-1-eng-GB/esmo23_20.10_gi-proferred_lordick_i770.jpg)
First-line pembrolizumab combination significantly improves PFS in HER2-positive metastatic G/GEJ adenocarcinoma
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
![ESMO23_20.10_GI Proffered_Smyth](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_gi-proffered_smyth/18320586-1-eng-GB/esmo23_20.10_gi-proffered_smyth_i770.jpg)
Data are still insufficient to recommend immune checkpoint inhibitors in perioperative therapy for gastric/gastro-oesophageal junction cancers
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future
![ESMO23_20.10_GI Proffered_Nillson](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/20.10.2023/esmo23_20.10_gi-proffered_nillson/18320544-1-eng-GB/esmo23_20.10_gi-proffered_nillson_i770.jpg)
Study shows noninferior overall survival with active surveillance compared with surgery in some oesophageal cancers
Findings from the SANO trial also reported clinically complete responses after neoadjuvant chemoradiotherapy
![Chiara Cremolini](/var/esmo/storage/images/media/esmo-daily-reporter/images/portraits/chiara-cremolini/18272158-1-eng-GB/chiara-cremolini_i770.jpg)
Are we over-treating patients with locally advanced rectal cancer?
Recently presented results suggest that a subset of patients with early stage rectal cancer could skip pre-operative radiotherapy, thus raising some questions about the standard of care
![Editorial_Cell Therapy](/var/esmo/storage/images/media/esmo-daily-reporter/images/editorials/editorial_cell-therapy/18279306-1-eng-GB/editorial_cell-therapy_i770.jpg)
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients